Nuvo Research Granted US Patent for Topical Onychomycosis Formulation

The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2031. Nuvo has pioneered formulations utilizing chemical penetration enhancers in other topically applied drug products including the Pennsaid^® and Pennsaid 2%.

"Onychomycosis is an uncomfortable and embarrassing condition that affects approximately 10% of the population," said Dan Chicoine, Nuvo's Chairman and Co-CEO. "Existing therapies have side effects or limited efficacy creating a significant market opportunity for a topical product that can safely eradicate the fungal infection.  These patents afford Nuvo another avenue to realize value from our investments and scientific accomplishments in delivering drugs into or through skin and nails.  Our strategy is to make this formulation available for out-licensing collaborations with partners who will fund completion of the development program."